Attached files
| file | filename |
|---|---|
| 10-K - 10-K - Sierra Oncology, Inc. | srra-10k_20201231.htm |
| EX-32.2 - EX-32.2 - Sierra Oncology, Inc. | srra-ex322_7.htm |
| EX-32.1 - EX-32.1 - Sierra Oncology, Inc. | srra-ex321_6.htm |
| EX-31.2 - EX-31.2 - Sierra Oncology, Inc. | srra-ex312_8.htm |
| EX-31.1 - EX-31.1 - Sierra Oncology, Inc. | srra-ex311_9.htm |
| EX-21.1 - EX-21.1 - Sierra Oncology, Inc. | srra-ex211_11.htm |
| EX-10.15 - EX-10.15 - Sierra Oncology, Inc. | srra-ex1015_241.htm |
| EX-10.14 - EX-10.14 - Sierra Oncology, Inc. | srra-ex1014_349.htm |
| EX-10.12 - EX-10.12 - Sierra Oncology, Inc. | srra-ex1012_348.htm |
| EX-10.5 - EX-10.5 - Sierra Oncology, Inc. | srra-ex105_316.htm |
| EX-10.3 - EX-10.3 - Sierra Oncology, Inc. | srra-ex103_315.htm |
EXHIBIT 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the incorporation by reference in Registration Statement Nos. 333-205693, 333-209897, 333-216392, 333-223253, 333-228263, 333-229933, 333-236854 and 333-241414 on Form S-8, and Registration Statement Nos. 333-225650, 333-234554 and 333-241443 on Form S-3 of our report dated March 11, 2021, relating to the consolidated financial statements of Sierra Oncology, Inc. and subsidiaries (the “Company”) appearing in this Annual Report on Form 10-K of the Company for the year ended December 31, 2020.
/s/ Deloitte & Touche LLP
Grand Rapids, Michigan
March 11, 2021